Suchergebnisse - Luis Paz‐Ares

Treffer weiter einschränken
  1. 1
    Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain

    Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain von Luis Paz-Ares, Luís Manso, Guillermo de Velasco

    Veröffentlicht 2020
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  2. 2
    <i>KRAS</i>oncogene in lung cancer: focus on molecularly driven clinical trials

    <i>KRAS</i>oncogene in lung cancer: focus on molecularly driven clinical trials von Emmanuelle Kempf, Benoı̂t Rousseau, Benjamin Besse, Luis Paz‐Ares

    Veröffentlicht 2016
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  3. 3
    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects

    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects von Solange Peters, Luis Paz‐Ares, Roy S. Herbst, Martin Reck

    Veröffentlicht 2022
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Biological therapies in nonsmall cell lung cancer

    Biological therapies in nonsmall cell lung cancer von Jon Zugazagoitia, Sonia Molina‐Pinelo, Fernando López‐Ríos, Luis Paz‐Ares

    Veröffentlicht 2017
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy

    Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy von David P. Carbone, David R. Gandara, Scott Antonia, Christoph Zielinski, Luis Paz‐Ares

    Veröffentlicht 2015
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  6. 6
    Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

    Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors von David Westover, J. Zugazagoitia, Byoung Chul Cho, Christine M. Lovly, Luis Paz‐Ares

    Veröffentlicht 2018
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

    Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Pati... von Jonathan W. Goldman, Peipei Shi, Martin Reck, Luis Paz‐Ares, Andrew Koustenis, Karla Hurt

    Veröffentlicht 2015
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

    Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer von Bruce G. Robinson, Luis Paz‐Ares, Annetta Krebs, James R. Vasselli, Robert I. Haddad

    Veröffentlicht 2010
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  9. 9
    Current Challenges in Cancer Treatment

    Current Challenges in Cancer Treatment von Jon Zugazagoitia, Cristiano Guedes, Santiago Ponce, Irene Ferrer, Sonia Molina‐Pinelo, Luis Paz‐Ares

    Veröffentlicht 2016
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  10. 10
    KRAS-Mutant non-small cell lung cancer: From biology to therapy

    KRAS-Mutant non-small cell lung cancer: From biology to therapy von Irene Ferrer, Jon Zugazagoitia, Stephan Herbertz, William J. John, Luis Paz‐Ares, Gerald Schmid‐Bindert

    Veröffentlicht 2018
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  11. 11
    Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study

    Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study von Luis Paz‐Ares, Ádám Gondos, Diego Saldaña, Marlène Thomas, Céline Mascaux, Lukas Bubendorf, Fabrice Barlési

    Veröffentlicht 2022
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  12. 12
    Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis

    Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis von Luis Paz‐Ares, Denis Soulières, I. Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer

    Veröffentlicht 2010
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  13. 13
    Lung cancer: current therapies and new targeted treatments

    Lung cancer: current therapies and new targeted treatments von Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, Regina Kwon, Walter J. Curran, Yi‐Long Wu, Luis Paz‐Ares

    Veröffentlicht 2016
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  14. 14
    Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study

    Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study von Mustafa Özgüroğlu, Jonathan W. Goldman, Yuanbin Chen, Marina Chiara Garassino, Nenad Medić, Helen Mann, P. Chugh, Tapashi Dalvi, Luis Paz‐Ares

    Veröffentlicht 2025
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

    Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus... von Luis Paz‐Ares, Mark A. Socinski, Javad Shahidi, R.R. Hozak, Victoria Soldatenkova, Raffael Kurek, Marileila Varella‐Garcia, N. Thatcher, Fred R. Hirsch

    Veröffentlicht 2016
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  16. 16
    ATLANTIS: A Phase III Study of Lurbinectedin/Doxorubicin Versus Topotecan or Cyclophosphamide/Doxorubicin/Vincristine in Patients with Small-Cell Lung Cancer Who Have Failed one Prior Platinum-Containing Line

    ATLANTIS: A Phase III Study of Lurbinectedin/Doxorubicin Versus Topotecan or Cyclophosphamide/Doxorubicin/Vincristine in Patients with Small-Cell Lung Cancer Who Have Failed one Pr... von Anna F. Farago, Benjamin J. Drapkin, Jose Antonio Lopez-Vilarino de Ramos, Carlos M. Galmarini, Rafael N. Nuñez, Carmen Kahatt, Luis Paz‐Ares

    Veröffentlicht 2018
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  17. 17
    Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

    Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow... von Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino, Takayasu Kurata, Ying Cheng, Erin Jensen, Mark Shamoun, Kumar Rajagopalan, Luis Paz‐Ares

    Veröffentlicht 2024
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials

    Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials von Alberto Carretero-González, David Lora, Ismael Ghanem, Jon Zugazagoitia, Daniel Castellano, Juan Manuel Sepúlveda-Sánchez, José A. López-Martín, Luis Paz‐Ares, Guillermo de Velasco

    Veröffentlicht 2018
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medi... von Pilar Garrido, Esther Conde, Javier de Castro, Javier Gómez‐Román, Enriqueta Felip, Lara Pijuán, Dolores Isla, Julián Sanz‐Ortega, Luis Paz‐Ares, Fernando López‐Ríos

    Veröffentlicht 2019
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Med... von Dolores Isla, María D. Lozano, Luis Paz‐Ares, Clara Salas, Javier de Castro, Esther Conde, Enriqueta Felip, Javier Gómez‐Román, Pilar Garrido, Ana B. Enguita

    Veröffentlicht 2022
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: